On Sept. 13, 2001, the Food and Drug Administration (FDA) announced it had approved Genentech’s  request for it’s biologics license application for Alteplase, to provide for a 2 mg vial strength and a new indication for the restoration of function to central venous access devices (as assessed by the ability to withdraw blood).

The labeling had the trade name Cathflo Activase.